

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

To Our Shareholders:

(Securities Code: 2183)

June 8, 2022

1-6-1 Miyahara, Yodogawa-ku, Osaka

Linical Co., Ltd.

Kazuhiro Hatano, President & Chief Executive Officer

Notice of the 17th Ordinary General Meeting of Shareholders

We would like to express our appreciation for your continued support and patronage.

Please be notified that the 17th Ordinary General Meeting of Shareholders of Linical Co., Ltd. (the "Company") will be held as described below.

You may exercise your voting rights in writing. We kindly request you to read the following Reference Document for the General Meeting of Shareholders, indicate "for" or "against" on each agenda item on the voting form enclosed herewith, and return it no later than the end of business at 5:30 p.m. on Wednesday, June 22, 2022 (JST).

In light of the resurgence of new coronavirus infection (COVID-19), shareholders are encouraged to exercise their voting rights in writing (by mail) in advance in order to ensure their safety and prevent the spread of COVID-19, and refrain as much as possible from attending the General Meeting of Shareholders in person.

Details

- 1. Date and Time:** Thursday, June 23, 2022 at 10 a.m. (JST)
- 2. Venue:** 1-6-1 Miyahara, Yodogawa-ku, Osaka
Conference Room A, 3rd Floor, Shin-Osaka Brick Building
(Please refer to the attached "Guide Map to the Venue of the General Meeting of Shareholders.")
- 3. Agenda**
 - Items to be reported:**
 1. The business report, the consolidated financial statements and the results of consolidated financial statement audits by the Accounting Auditor and the Audit & Supervisory Board for the 17th business period (April 1, 2021 to March 31, 2022)
 2. The non-consolidated financial statements for the 17th business period (April 1, 2021 to March 31, 2022)
 - Items to be resolved:**
 - Proposal No. 1 Partial Amendment to the Articles of Incorporation
 - Proposal No. 2 Election of Nine (9) Executive Directors
 - Proposal No. 3 Election of One (1) Substitute Audit & Supervisory Board Member

Reference Documents for the General Meeting of Shareholders

Proposals and Reference Matters

Proposal No. 1: Partial Amendment to the Articles of Incorporation

1. Reasons for proposal

- (1) As the revised provisions provided for in the proviso to Article 1 of the Supplementary Provisions of the Act Partially Amending the Companies Act (Act No. 70 of 2019) are to be enforced on September 1, 2022, the Company proposes to make the following changes to its Articles of Incorporation in preparation for the introduction of the system for providing informational materials for the general meeting of shareholders in electronic format.
 - (i) Article 16, paragraph 1 of the proposed amendment stipulates that the Company will take measures for providing information that constitutes the content of reference documents for the general meeting of shareholders, etc. in electronic format.
 - (ii) Article 16, paragraph 2 of the proposed amendment establishes provisions to allow the Company to limit the scope of the items to be stated in the paper-based documents to be delivered to shareholders who requested the delivery of paper-based documents.
 - (iii) Since the provision regarding online disclosure and deemed provision of reference documents for the shareholders meeting, etc. (Article 16 of the current Articles of Incorporation) will no longer be required, they will be deleted.
 - (iv) Supplementary provisions regarding the effective date, etc. of the above new establishment and deletion of provisions will be established.
- (2) In order to ensure the flexibility of the management of the Board of Directors and to build a management system that can respond promptly to changes in the management environment as well as to further strengthen and enhance the management base, necessary changes will be made to the provisions of Article 22 of the current Articles of Incorporation (CEO and Executive Directors).

2. Details of the amendments

Details of the amendment to the Articles of Incorporation are as follows.

(The parts to be amended are underlined.)

Current Articles of Incorporation	Proposed amendments
<p><u>(Online Disclosure and Deemed Provision of Reference Documents for the Shareholders Meeting, Etc.)</u></p> <p><u>Article 16 The Company may deem that information relating to matters to be stated or indicated in the reference documents for the Shareholders Meeting, business report, non-consolidated financial statements and consolidated financial statements has been provided to shareholders by disclosing such information via the Internet in accordance with the applicable Ordinance of the Ministry of Justice.</u></p> <p style="text-align: center;"><Newly established></p>	<p style="text-align: center;"><Deleted></p> <p><u>(Measures, etc. for Providing Information in Electronic Format)</u></p> <p><u>Article 16 When the Company convenes a general meeting of shareholders, it shall take measures for providing information that constitutes the content of reference documents for the general meeting of shareholders, etc. in electronic format.</u></p> <p><u>2 Among items for which the measures for providing information in electronic format will be taken, the Company may choose not to state all or some of those items designated by the Ordinance of the Ministry of Justice in the paper-based documents to be delivered to shareholders who requested the delivery of paper-based documents by the record date of voting rights.</u></p>

Current Articles of Incorporation	Proposed amendments
(CEO and Executive Directors) Article 22 (Text omitted) 2 By resolution of the Board of Directors, <u>one Chairman of the Board, one President, and a few Executive Vice Presidents, Senior Managing Directors and Managing Directors may be elected.</u>	(CEO and Executive Directors) Article 22 (Unchanged) 2 <u>One President shall be appointed</u> by resolution of the Board of Directors. <u>By resolution of the Board of Directors as necessary, the Company may appoint a few Executive Directors with special titles among Executive Directors.</u>
<Newly established>	(Supplementary Provisions) (Transitional Measures, etc. for Providing Information in Electronic Format) Article 1 <u>The deletion of Article 16 (Online Disclosure and Deemed Provision of Reference Documents for the Shareholders Meeting, Etc.) of the Articles of Incorporation before amendment and the new establishment of Article 16 (Measures, etc. for Providing Information in Electronic Format) of the Articles of Incorporation after amendment shall take effect as of September 1, 2022 (hereinafter referred to as the “Effective Date”), which is the enforcement date of the revised provisions provided for in the proviso to Article 1 of the Supplementary Provisions of the Act Partially Amending the Companies Act (Act No. 70 of 2019).</u> 2 <u>Notwithstanding the provisions of the preceding paragraph, Article 16 of the Articles of Incorporation before amendment shall remain effective regarding any general meeting of shareholders held on a date within six months from the Effective Date.</u> 3 <u>This Article shall be deleted on the date when six months have elapsed from the Effective Date or three months have elapsed from the date of the general meeting of shareholders in the preceding paragraph, whichever is later.</u>

Proposal No. 2: Election of Nine (9) Executive Directors

The term of office of all nine (9) Executive Directors will expire at the conclusion of this General Meeting of Shareholders.

Accordingly, the election of nine (9) Executive Directors is proposed.

The candidates for Executive Directors are as follows.

Candidate No. 1

Kazuhiro Hatano (March 17, 1965) Reappointment

Number of the Company's shares owned: 742,000

Career summary, position and responsibility at the Company (significant concurrent positions)

April 1990	Joined Clinical Development Department of Maruho Co., Ltd.
July 1998	Joined Development Department of Meditech International Co., Ltd.
March 1999	Joined Development Unit of Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
September 2004	Director of Aurora Co., Ltd.
June 2005	Founded the Company President & CEO and Representative Executive Director (current position)
February 2010	Head of Clinical Development Unit
September 2015	Head of Corporate Planning Office (current position)
December 2020	Head of Clinical Development Unit (current position)
July 2021	Head of Marketing Planning Office (current position)

Reasons for nomination as a candidate for Executive Director

Kazuhiro Hatano has been nominated as a candidate for Executive Director because he has been leading the management of the entire Group as a core founding member of the Company, backed by his extensive knowledge and experience in new drug development at major domestic pharmaceutical companies, etc., promoting globalization of the Group, formulating and executing strategies for medium-term growth, and achieving satisfactory business results. The Company proposes his election as an Executive Director in order to realize business growth and enhance corporate value of the Group by having him continuously demonstrate his abilities.

Candidate No. 2

Keigo Tsujimoto (February 22, 1964) Reappointment

Number of the Company's shares owned: 1,024,200

Career summary, position and responsibility at the Company (significant concurrent positions)

April 1986	Joined Osaka Branch of Dainippon Pharmaceutical Co., Ltd. (currently Sumitomo Pharma Co., Ltd.)
August 1990	Joined Kano General Hospital of Heartfull Group
April 1993	Joined Development Department of Meditech International Co., Ltd.
June 1999	Joined Clinical Development Department of Shin Nippon Biomedical Laboratories, Ltd.
August 1999	Joined Clinical Development Department of EPS Corporation
September 2001	Joined Clinical Development Department of Senju Pharmaceutical Co., Ltd.
September 2002	Joined Development Department of Ferring Pharmaceuticals Co., Ltd.
December 2007	Executive Director of the Company
February 2008	Executive Vice President and Executive Director (current position)
July 2008	President & CEO of LINICAL USA, INC.
April 2009	Head of Quality Control Department of the Company
July 2011	Head of Global Business Development Office
September 2015	President & CEO of LINICAL Europe Holding GmbH Director of LINICAL USA, INC.
April 2018	Director of Linical Accelovance America, Inc.
December 2020	Head of Europe and U.S. Business of the Company (current position) Head of Global Business Unit (current position) Chairman & Director of LINICAL Europe Holding GmbH (current position) Chairman & Director of LINICAL USA, INC. (current position) Chairman & Director of Linical Accelovance America, Inc. (current position)
April 2021	Director of LINICAL KOREA CO., LTD.(current position) Director of LINICAL TAIWAN CO., LTD. (current position) Director of Linical China Co., Ltd. (current position)

Reasons for nomination as a candidate for Executive Director

Keigo Tsujimoto has been nominated as a candidate for Executive Director because he has been leading the Company's global strategy mainly as Head of Europe and U.S. Business of the Company, based on his extensive knowledge and experience in new drug development at foreign pharmaceutical companies, etc. The Company proposes his election as an Executive Director in order to realize business growth and enhance corporate value of the Group by having him continuously demonstrate his abilities.

Candidate No. 3

Jun Kawai (October 26, 1968) Reappointment

Number of the Company's shares owned: 600,400

Career summary, position and responsibility at the Company (significant concurrent positions)

April 1993 Joined Research Division, Nihon Schering K.K. (currently Bayer Yakuhin, Ltd.)

November 1996 Joined Development Department of Meditech International Co., Ltd.

June 1999 Joined Development Division of SmithKline Beecham Co., Ltd. (currently GlaxoSmithKline K.K.)

July 2001 Joined Development Division of Shionogi & Co., Ltd.

September 2004 Director of Aurora Co., Ltd.

December 2005 Executive Director of the Company

April 2007 Deputy Director of Clinical Development Unit (Osaka)

Director of Development Department 3

April 2008 Executive Vice President and Executive Director

May 2013 President & CEO of LINICAL TAIWAN CO., LTD.

CEO of LINICAL KOREA CO., LTD.

June 2013 Executive Vice President and Executive Director of the Company

June 2016 Supervisory Director of the Asian Region

Executive Vice President and Executive Director (current position)

July 2017 Head of Quality Control (QC) Unit

Director of LINICAL TAIWAN CO., LTD.

May 2019 President & CEO of Linical China Co., Ltd.

July 2019 Director of LINICAL KOREA CO., LTD.

December 2019 President & CEO of LINICAL TAIWAN CO., LTD.

December 2020 Director of U.S. Business of the Company

May 2021 Director, President & CEO of LINICAL USA, INC. (current position)

Director, President & CEO of Linical Accelovance America, Inc. (current position)

Reasons for nomination as a candidate for Executive Director

Jun Kawai has been nominated as a candidate for Executive Director because he has served as Head of Quality Control (QC) Unit and Supervisory Director of the Asian Region, based on his extensive knowledge and experience in new drug development at major domestic pharmaceutical companies. Since May 2021, he has been leading the global strategy as Director, President & CEO of LINICAL USA, INC., and Director, President & CEO of Linical Accelovance America, Inc. The Company proposes his election as an Executive Director in order to realize business growth and enhance corporate value of the Group by having him continuously demonstrate his abilities.

Candidate No. 4

Akihiro Takahashi (November 13, 1967) Reappointment

Number of the Company's shares owned: 741,600

Career summary, position and responsibility at the Company (significant concurrent positions)

April 1990	Joined Research Division of Toyama Chemical Co., Ltd.
March 1995	Master's degree at the Graduate School of Medical Sciences at the University of Tsukuba
April 1995	Joined Development Department of Meditech International Co., Ltd.
March 1999	Joined Development Unit of Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
September 2004	Director of Aurora Co., Ltd.
June 2005	Founded the Company, Executive Vice President and Executive Director
April 2007	Executive Vice President and Executive Director (current position) Chief Financial Officer (CFO) and Director of Administrative Department
April 2009	Head of Administrative Unit (current position)
May 2013	Director of LINICAL TAIWAN CO., LTD. Director of LINICAL KOREA CO., LTD.(current position)
May 2019	Director of Linical China Co., Ltd. (current position)
November 2019	Chief Information Officer(CIO)
December 2020	Director of LINICAL TAIWAN CO., LTD. (current position)

Reasons for nomination as a candidate for Executive Director

Akihiro Takahashi has been nominated as a candidate for Executive Director because he has a deep knowledge of the Company's business due to his extensive knowledge and experience in new drug development at major domestic pharmaceutical companies, etc., and has a track record of handling overall management operations such as general affairs and accounting of the entire Group as the Head of Administrative Unit as a core founding member of the Company. The Company proposes his election as an Executive Director in order to realize business growth and enhance corporate value of the Group by having him continuously demonstrate his abilities.

Candidate No. 5

Masaya Miyazaki (November 16, 1971) Reappointment

Number of the Company's shares owned: 600,200

Career summary, position and responsibility at the Company (significant concurrent positions)

April 1996	Joined Development Department of Meditech International Co., Ltd.
August 1999	Joined Development Unit of Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
March 2003	Joined Development Division of Ferring Pharmaceuticals Co., Ltd.
June 2006	Executive Director of the Company
April 2007	Deputy Head of Clinical Development Unit (Tokyo)
June 2013	Executive Vice President and Executive Director (current position)
January 2017	Head of Global Business Development Office
July 2017	Head of Clinical Development Unit
January 2019	Head of Global Business Development Unit
May 2019	Director of Linical China Co., Ltd.
July 2019	Director of LINICAL KOREA CO., LTD.(current position)
January 2020	Director of LINICAL TAIWAN CO., LTD.
December 2020	Head of Asia Business of the Company (current position) President & CEO of LINICAL TAIWAN CO., LTD. (current position) President & CEO of Linical China Co., Ltd. (current position)

Reasons for nomination as a candidate for Executive Director

Masaya Miyazaki has been nominated as a candidate for Executive Director because he had served as Head of Clinical Development Unit and Head of Global Business Development Unit of the Company, and has been leading the Company's Asian business since December 2020, based on his extensive knowledge and experience in new drug development at major domestic pharmaceutical companies, etc. The Company proposes his election as an Executive Director in order to realize business growth and enhance corporate value of the Group by having him continuously demonstrate his abilities.

Candidate No. 6

Isao Sakamoto (March 25, 1976) Reappointment

Number of the Company's shares owned: 735,800

Career summary, position and responsibility at the Company (significant concurrent positions)

April 2000	Joined Development Unit of Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
July 2005	Joined the Company
October 2005	Audit & Supervisory Board Member of Aurora Co., Ltd.
April 2007	Associate Director of Development Department 4 of the Company
June 2007	Executive Director (current position)
July 2008	Executive Director of LINICAL USA, INC.
July 2009	Director of Development Department 4 of the Company
May 2013	Director of LINICAL TAIWAN CO., LTD. Director of LINICAL KOREA CO., LTD.
May 2014	Director of Asia Development Department of Global Business Development Office
July 2015	Head of Oncology Business Unit
September 2015	President & CEO of LINICAL USA, INC.
April 2016	Director of Global Project Management Department of Global Business Development Office of the Company Director of Global Clinical Operation Department of Global Business Development Office of the Company
April 2017	Head of Global Business Development Unit
April 2018	Chairman & President of Linical Accelovance America, Inc.
July 2018	Chairman, President & CEO of LINICAL USA, INC. Chairman, President & CEO of Linical Accelovance America, Inc.
August 2019	Head of Oncology Business Unit of Clinical Development Unit of the Company
December 2020	Director of Europe Business Director, President & CEO of LINICAL USA, INC. Director, President & CEO of Linical Accelovance America, Inc.
May 2021	Director & CEO of LINICAL Europe Holding GmbH (current position)

Reasons for nomination as a candidate for Executive Director

Isao Sakamoto has been nominated as a candidate for Executive Director because he has rebuilt the U.S. business as Chairman, President & CEO of LINICAL USA, INC. and Chairman, President & CEO of Linical Accelovance America, Inc., based on his extensive knowledge and experience in new drug development at major domestic pharmaceutical companies. Since May 2021, he has been leading the global strategy as Director & CEO of LINICAL Europe Holding GmbH. The Company proposes his election as an Executive Director in order to realize business growth and enhance corporate value of the Group by having him continuously demonstrate his abilities.

Candidate No. 7

Shiori Yamaguchi (November 11, 1975) Reappointment

Number of the Company's shares owned: 80,800

Career summary, position and responsibility at the Company (significant concurrent positions)

April 1998	Joined Omichi Hospital of Omichikai-Group
April 2000	Joined Development Unit of Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.) (temporary employee)
July 2003	Joined EP-Link Co., Ltd. (currently EP-Sogo Co., Ltd.)
September 2004	Joined Aurora Co., Ltd.
June 2005	Audit & Supervisory Board Member of the company
October 2005	Director of Aurora Co., Ltd.
June 2007	Joined the Company, Head of Audit Office (current position)
June 2009	Executive Director (current position) Chief Compliance Officer (CCO) (current position)

Reasons for nomination as a candidate for Executive Director

Shiori Yamaguchi has been nominated as a candidate for Executive Director because she has a deep knowledge of the Company's business due to her extensive knowledge and experience in new drug development at major domestic pharmaceutical companies, etc., and has a track record of establishing an internal control system as the Company's Chief Compliance Officer (CCO). The Company proposes her election as an Executive Director in order to realize business growth and enhance corporate value of the Group by having her continuously demonstrate her abilities.

Candidate No. 8

Masafumi Nogimori (December 21, 1947)

Reappointment	Outside	Independent Officer
---------------	---------	---------------------

Number of the Company's shares owned: 0

Career summary, position and responsibility at the Company (significant concurrent positions)

April 1970	Joined Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
June 1997	Director of Fujisawa Pharmaceutical Co., Ltd.
July 1998	President of Fujisawa GmbH
June 2000	Resigned as Director of Fujisawa Pharmaceutical Co., Ltd. due to the introduction of the Executive Officer system
	Executive Officer of Fujisawa Pharmaceutical Co., Ltd.
April 2001	Executive Officer, Deputy General Manager of Medicine Business and General Manager of Medicine Planning Department of Fujisawa Pharmaceutical Co., Ltd.
June 2001	Executive Vice President in Global Corporate Strategic Planning of Medicine Planning Department of Fujisawa Pharmaceutical Co., Ltd.
June 2003	Executive Vice President of Fujisawa Pharmaceutical Co., Ltd.
June 2004	Senior Executive Vice President of Fujisawa Pharmaceutical Co., Ltd.
April 2005	Executive Vice President and Representative Director of Astellas Pharma Inc.
June 2006	President & CEO and Representative Director of Astellas Pharma Inc.
June 2011	Chairman and Representative Director of Astellas Pharma Inc.
June 2016	Retired as Chairman and Representative Director of Astellas Pharma Inc.
June 2017	Outside Director of Daicel Corporation (current position)
	Outside Director of Mitsui Fudosan Co., Ltd. (current position)
July 2017	Outside Executive Director of the Company (current position)

Reasons for nomination as a candidate for Outside Executive Director and expected roles

Masafumi Nogimori has been nominated as a candidate for Outside Executive Director because he has held important positions in Japan and overseas since his time at the former Fujisawa Pharmaceutical Co., Ltd., including President & CEO of Astellas Pharma Inc., and has deep knowledge of the pharmaceutical industry, extensive management experience, and deep insight into corporate governance. Based on these points, the Company has determined that he will continue to play an important role in supervising the execution of business and enhancing corporate value as an Outside Executive Director, and therefore nominated him as a candidate for Outside Executive Director.

Candidate No. 9

Akio Osawa (November 21, 1942)

Reappointment	Outside	Independent Officer
---------------	---------	---------------------

Number of the Company's shares owned: 0

Career summary, position and responsibility at the Company (significant concurrent positions)

April 1966	Joined Ciba Products Co., Ltd. (currently Novartis Pharma K.K.)
April 1977	Product Manager of Psychiatry & Neurology Product Group
September 1980	Japan Desk of Ciba-Geigy (Switzerland)
July 1987	Head of Marketing Planning Department of Pharmaceutical Division
July 1993	Managing Director & Head of the Pharmaceutical Division
April 1997	Director & Vice President of Novartis Pharma K.K.
March 1999	Retired as Director & Vice President of Novartis Pharma K.K.
July 1999	Director & Vice President of Weyth-Lederle Japan (currently Pfizer Japan Inc.)
March 2002	Retired as Vice President of Weyth-Lederle Japan
April 2002	President of Nippon Boehringer Ingelheim Co., Ltd.
November 2007	Retired as President of Nippon Boehringer Ingelheim Co., Ltd. Advisor of Nippon Boehringer Ingelheim Co., Ltd.
November 2008	Retired as Advisor of Nippon Boehringer Ingelheim Co., Ltd.
January 2009	Director of Atani Co., Ltd.
August 2009	Advisor, CM Plus Corporation (current position)
December 2012	Retired as Director of Atani Co., Ltd.
July 2018	Outside Executive Director of the Company (current position)

Reasons for nomination as a candidate for Outside Executive Director and expected roles

Akio Osawa has been nominated as a candidate for Outside Executive Director because he has held important positions such as President and Vice President at several Japanese subsidiaries of major foreign pharmaceutical companies, and has deep knowledge of the pharmaceutical industry, extensive management experience, and deep insight into corporate governance. Based on these points, the Company has determined that he will continue to play an important role in supervising the execution of business and enhancing corporate value as an Outside Executive Director, and therefore nominated him as a candidate for Outside Executive Director.

- (Notes)
1. There is no special interest between any of the candidates and the Company.
 2. Masafumi Nogimori and Akio Osawa are currently Outside Executive Directors of the Company, and their term in office as Outside Executive Directors will be five years for Mr. Nogimori and four years for Mr. Osawa at the conclusion of the General Meeting of Shareholders.
 3. Masafumi Nogimori and Akio Osawa are the candidate for Outside Executive Directors. The Company appointed Masafumi Nogimori and Akio Osawa as Independent Officers as set forth by Tokyo Stock Exchange, Inc.
 4. The Company has entered into agreements with Masafumi Nogimori and Akio Osawa to limit their liability for damages under Article 423, paragraph 1 of the Companies Act. If their reappointment is approved, the Company plans to continue the contract with them. The maximum amount of liability under the agreement is the minimum liability amount stipulated in Article 425, paragraph 1 of the Companies Act.
 5. The Company and an insurance company have entered into a directors' and officers' liability insurance contract as prescribed in Article 430-3, paragraph 1 of the Companies Act to cover legal damages and expenses for litigation in the event that a claim for damages is made against the insured during the insurance period due to an act committed by the insured based on his or her status under the insurance contract. If each candidate is elected as an Executive Director and assumes office, he or she shall be the insured under the relevant insurance contract. The policy is scheduled to be renewed with the same content at the next renewal.

Proposal No. 3: Election of One (1) Substitute Audit & Supervisory Board Member

In order to prepare for the case where the number of Audit & Supervisory Board Members falls short of the number stipulated by laws and regulations, the Company requests the election of one (1) substitute Audit & Supervisory Board Member.

The election of substitute Audit & Supervisory Board Members may be cancelled only prior to the assumption of office by resolution of the Board of Directors with the consent of the Audit & Supervisory Board.

This proposal has been approved by the Audit & Supervisory Board.

The candidate for substitute Audit & Supervisory Board Member is as follows.

Kyoichi Shimomura (January 15, 1944) Outside

Number of the Company's shares owned: 4,500

Career summary and position at the Company (significant concurrent positions)

April 1971	Joined Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
April 1993	Director of Development Institute I
July 1996	Director of Tsukuba Research Laboratories and Director of Exploratory Research Laboratories
October 1998	Senior Researcher of Institute of Pharmacology of Fujisawa Pharmaceutical Co., Ltd.
December 1998	Director and General Manager of Development Research Division of Santen Pharmaceutical Co., Ltd.
July 1999	Executive Officer and General Manager of Development Research Division
December 2002	Executive Officer and General Manager of Development Research Center
December 2004	Retired from Santen Pharmaceutical Co., Ltd.
April 2005	Professor of School of Pharmacy of Shujitsu University
April 2009	Part-time Lecturer of School of Pharmacy of Shujitsu University
January 2010	Advisor of the Company
June 2020	Audit & Supervisory Board Member of the Company

Reasons for nomination as a candidate for Outside Audit & Supervisory Board Member

Kyoichi Shimomura has been nominated as a candidate for Outside Audit & Supervisory Board Member because he has experience leading the research and development of new drugs as Director of Research Laboratories and Executive Officer of the Development Research Center at major Japanese pharmaceutical companies. The Company proposes his election as substitute Outside Audit & Supervisory Board Member in order to reflect his abundant experience and knowledge gained at other companies in the Company's audit operations.

- (Notes)
1. There is no special interest between the candidate and the Company.
 2. Kyoichi Shimomura is the candidate for substitute Outside Audit & Supervisory Board Member.
 3. Kyoichi Shimomura meets the requirements of an Independent Officer by the Tokyo Stock Exchange. If Kyoichi Shimomura assumes office as Audit & Supervisory Board Member, the Company plans to appoint Kyoichi Shimomura as Independent Officer as set forth by Tokyo Stock Exchange, Inc.
 4. If Kyoichi Shimomura assumes office as Audit & Supervisory Board Member, the Company plans to enter into an agreement with him to limit his liability for damages under Article 423, paragraph 1 of the Companies Act. The maximum amount of liability under the agreement will be the minimum liability amount stipulated in Article 425, paragraph 1 of the Companies Act.
 5. The Company and an insurance company have entered into a directors' and officers' liability insurance contract as prescribed in Article 430-3, paragraph 1 of the Companies Act to cover legal damages and expenses for litigation in the event that a claim for damages is made against the insured during the insurance period due to an act committed by the insured based on his or her status under the insurance contract. If Kyoichi Shimomura assumes office as Audit & Supervisory Board Member, he shall be the insured under the relevant insurance contract.